Par contre, pas d'effets secondaires sérieux (j'imagine que les avc sont
pris en compte...). En plus, c'est assez fréquent qu'un patient retrouve
un rythme sinusal après une dose de BB, d'anticalcique ou de lanoxin.
*Martin Chénier*
/[EMAIL PROTECTED]/
Michael Garner a écrit :
Très intéressant, mais si ça augmente les chances de contrôler à la
fois la fréquence et le rythme, ça suggère que l'on puisse risquer de
convertir des FA chroniques, avec les risques associés d'embolie.
On ne devrait logiquement ne s'en servir que dans les FA aigues, en
autant que l'on puisse être certain qu'une FA est aigue
Ou suis-je dans les pommes de terre ? (puisque la France nous lit, je
ne voudrai pas les dérouter avec des termes comme patates)
Michel Garner
On 16-Sep-07, at 5:49 PM, Alain Vadeboncoeur wrote:
Très intéressant.
Am J Cardiol. 2007 Jun 15;99(12):1726-32. Epub 2007 Apr
26.<http---linkinghub.elsevier.com-ihub-images-PubMedLink.gif> Links
*Meta-analysis of magnesium therapy for the acute management of
rapid atrial fibrillation.*
*Onalan O*, *Crystal E*, *Daoulah A*, *Lau C*, *Crystal A*,
*Lashevsky I*.
Arrhythmia Services, Division of Cardiology, Sunnybrook Health
Sciences Centre, University of Toronto, Ontario, Canada.
[EMAIL PROTECTED]
The profile of electrophysiologic effects of magnesium on the
heart suggests that magnesium might be effective in the treatment
of atrial fibrillation (AF) in terms of rhythm and rate control.
We aimed to investigate the efficacy of magnesium administration
in the acute treatment of rapid AF. Randomized controlled trials
comparing intravenous magnesium versus placebo or antiarrhythmic
agents for the acute management of rapid AF were included. Nine
electronic databases were searched for relevant trials from the
earliest possible dates through June 2005, as were abstract books
from 8 cardiovascular meetings held in the past 10 years. We
analyzed all outcomes using a fixed-effect model because of the
low number of trials in each comparison. The results were
expressed as relative risks (RRs) or odds ratios (ORs) for
dichotomous outcomes and weighted mean differences for continuous
outcomes, along with their 95% confidence intervals (CIs). Data
were pooled for 4 trials (n=303) and 8 trials (n=476),
respectively, for rate control (<100 beats/min) and rhythm
control. Magnesium was effective in achieving rate control (OR
1.96, 95% CI 1.24 to 3.08) or rhythm control (OR, 1.60, 95% CI
1.07 to 2.39). An overall response was achieved in 86% and 56% of
patients in the magnesium and control groups, respectively (OR
4.61 95% CI 2.67 to 7.96). Time to response (in hours) was
significantly shorter in the magnesium group (weighted mean
difference, -6.98; 95% CI -9.27 to -4.68). The risk of having a
major adverse effect in the magnesium group was similar to that in
the placebo group (RR 0.85, 95% CI 0.44 to 1.61). In conclusion,
the present meta-analysis of published data suggests that
intravenous magnesium administration is an effective and safe
strategy for the acute management of rapid AF.
J'avais déjà essayé une fois, il y a longtemps.
Je m'y mets dès cette semaine.
Alain
*From:* [email protected] [mailto:[EMAIL PROTECTED] *On Behalf Of
*Martin Chénier
*Sent:* 16 septembre 2007 15:23
*To:* [email protected]
*Subject:* URG-L: Magnésium et FA
Est-ce que certains d'entre vous ont lu l'article suivant :
Meta-Analysis of Magnesium Therapy for the Acute Management of
Rapid Atrial Fibrillation. /Am J Cardiol/ 2007;99:1726-1732.
Utilisez-vous le sulfate de Mg dans la FA/Flutter rapide?
--
*Martin Chénier*
/[EMAIL PROTECTED]/
